# CAN SLIM Progress Board

Last updated: 2026-09-10

## Overall project progress

Estimated overall research-program progress: **~52%**.

This number measures completion of the independent CAN SLIM research program (data, methodology, experiments, robustness, validation), **not** how literally TrendFoll implements CAN SLIM.

| Area | Status | Notes |
|---|---|---|
| Project boundary / research governance | COMPLETE | CAN SLIM independent from TrendFoll |
| TrendFoll reference evidence | COMPLETE | Source of truth: `ussy-trendfoll`; comparator only |
| Expanded canonical universe | COMPLETE | 1,327 current Musaffa-compliant securities |
| SEC/PIT fundamental engineering | COMPLETE / FREEZE | Source of truth: `ussy-fundamentals` |
| R2 production contract + incremental updater | LIVE | `fundamentals/current.json` |
| C methodology | **C-v1 FROZEN** | EPS YoY >=25% AND revenue YoY >=25% |
| A methodology | **NEXT** | Must be frozen before performance testing |
| Independent CAN SLIM technical baseline | PENDING | Must be specified; do not inherit TrendFoll blindly |
| Entry Quality & Execution | PENDING | E0-E6 |
| C label/distribution audit | NEXT AFTER IMPLEMENTATION | No trading-performance tuning |
| C ablation | BLOCKED | Wait for independent technical baseline + C labeler |
| C+A ablation | BLOCKED | Wait for A-v1 freeze |
| Robustness / holdout | BLOCKED | After ablations |
| Institutional sponsorship (I) | DEFERRED | 13F/ownership work not started |
| Independent CAN SLIM production | BLOCKED | Evidence required |

## CAN SLIM component readiness

| Letter | Meaning | TrendFoll reference | CAN SLIM research status |
|---|---|---|---|
| C | Current Quarterly Earnings | Absent | Data ready; **C-v1 frozen** |
| A | Annual Earnings Growth | Absent | Data ready; methodology not frozen |
| N | New | Partial technical analogue | Independent specification pending |
| S | Supply and Demand | Volume analogue exists | Independent specification pending; float/shares later |
| L | Leader or Laggard | RS vs market/sector exists | Independent specification pending |
| I | Institutional Sponsorship | Absent | Deferred |
| M | Market Direction | SPY regime analogue exists | Independent specification pending |

## Fundamental production status

Current full universe: **1,327** securities.

| Readiness status | Count |
|---|---:|
| PASS_FULL | 857 |
| PASS_3Y_FALLBACK | 44 |
| Total production-ready | 901 |
| UNSUPPORTED_FPI | 247 |
| INSUFFICIENT_HISTORY | 106 |
| UNRESOLVED_CIK | 44 |
| RESIDUAL_PRODUCTION_COVERAGE | 17 |
| STRUCTURALLY_UNAVAILABLE_OR_UNSUPPORTED | 12 |

- Overall ready: **901 / 1,327 = 67.90%**
- Domestic SEC-supported ready: **901 / 1,035 = 87.05%**

Important: unsupported/missing/readiness states are **data states**, not automatic CAN SLIM economic verdicts.

## C-v1 frozen specification

```text
Latest usable quarter known at decision time
EPS YoY >= +25%
AND
Revenue YoY >= +25%
```

- availability governed by SEC `accepted_at` + configured market decision cutoff;
- `C_pass` is nullable (`TRUE` / `FALSE` / `NULL`);
- undefined negative/zero-base growth is never coerced to zero;
- turnaround from nonpositive EPS base is a separate state;
- acceleration is diagnostic in C-v1, not a hard gate;
- any post-performance change must become a new version (`C-v2`, etc.).

## Entry Quality & Execution workstream

| ID | Study | Status |
|---|---|---|
| E0 | Independent expanded-universe technical baseline / comparator design | PENDING |
| E1 | T-1 -> T0 signal-day shock | PENDING |
| E2 | T0 close -> H+1 open execution gap | PENDING |
| E3 | T0 pivot extension (3/5/8%) | PENDING |
| E4 | H+1 actual-fill pivot extension | PENDING |
| E5 | Interaction: shock + gap + extension | PENDING |
| E6 | Outcome diagnostics: MAE/MFE/PF/DD/etc. | PENDING |

## Research sequence

1. **Freeze A specification.**
2. Implement C-v1 PIT labeler and inspect TRUE/FALSE/NULL + reason-code distribution without trading-performance tuning.
3. Define the independent CAN SLIM technical baseline, using TrendFoll only as reference evidence.
4. Run Entry Quality diagnostics.
5. Implement A-v1 PIT labels and distribution audit.
6. Run ablations: technical baseline vs +C vs +C+A, plus entry-quality interactions.
7. Evaluate PF, PF ex-top10, return, max drawdown, trade count, subperiod stability, sector/symbol concentration.
8. Holdout / independent forward validation.
9. Consider a separate CAN SLIM production implementation only after evidence.
